Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy

Patients with chronic lymphocytic leukemia (CLL) who achieve blood or bone marrow (BM) undetectable minimal residual disease (U-MRD) status after first-line fludarabine, cyclophosphamide, and rituximab (FCR) have prolonged progression-free survival (PFS), when assessed by an assay with sensitivity 1...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood
Asıl Yazarlar: Thompson, Philip A., Srivastava, Jaya, Peterson, Christine, Strati, Paolo, Jorgensen, Jeffrey L., Hether, Tyler, Keating, Michael J., O’Brien, Susan M., Ferrajoli, Alessandra, Burger, Jan A., Estrov, Zeev, Jain, Nitin, Wierda, William G.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2019
Konular:
Lymphoid Neoplasia
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6887113/
https://ncbi.nlm.nih.gov/pubmed/31537528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019001077
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller